BridgeBio is demonstrably advanced its course of the novel therapy for ATTR-CM, employing the investigational drug. Initial clinical results suggests significant improvements for those diagnosed with the serious https://biotech641628.ssnblog.com/40696740/company-progresses-cardiac-amyloidosis-management-using-the-drug